• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Myomo Provides Highlights of Today's Investor & Analyst Day Event

    6/18/25 8:30:00 AM ET
    $MYO
    Industrial Specialties
    Health Care
    Get the next $MYO alert in real time by email

    Senior executives to provide an in-depth review of the Company's business model and discuss long-range aspirational financial metrics

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, will host an Investor & Analyst Day event today from 10 a.m. to 3 p.m. Eastern time during which management will provide an in-depth review of the Company's business model, provide a tour of its new headquarters and manufacturing facility and discuss long-range aspirational financial metrics. A live and archived webcast of the event is available here.

    To be held in Burlington, Mass. and virtually, highlights include the following:

    • As reported during the Company's Q1 2025 financial results conference call, lead generation has recovered from the challenges faced early in first quarter;
    • Management believes that the population of prospective MyoPro® patients remains largely untapped, and that the Company is not reaching a saturation point with its advertising;
    • Historical data will be presented showing that roughly half of pipeline adds come from leads that were generated one year or more ago;
    • Management will review efforts to improve Medicare Advantage reimbursement, including increasing success at winning appeals on behalf of patients;
    • Management will share that more than 27 million lives are covered by private payer contracts that have been executed or are in the process of being executed;
    • Participants will view a telehealth evaluation for a potential MyoPro candidate;
    • Participants will also experience a live demonstration of electromyogram signal capture and see how the MyoPro can improve a patient's ability to live independently;
    • Management will present its roadmap for product enhancements, new product introductions and sustaining engineering projects;
    • In-person participants will be given a tour of the Company's manufacturing operations while virtual participants will view a similar pre-recorded tour;
    • Management will discuss plans to increase manufacturing capacity, highlighting that existing manufacturing space plus new space expected to become available in July is sufficient to produce 250 MyoPros per month;
    • Management will review projects to reduce cost of goods that are expected to generate approximately 200 basis points of gross margin improvement on a quarterly basis by the end of 2026;
    • Several third-party orthotics and prosthetics ("O&P") providers will discuss their plans to provide the MyoPro to their patients;
    • Management will present a long-range financial model, with the goal of $100 million in annual revenue by 2028. Elements of the aspirational model to be discussed include:
      • $15 million of annual International revenue by 2028
      • $20 million of annual O&P channel revenue by 2028
      • Gross margin in the range of 70% to 72%
      • EBITDA margin in the range of 15% to 20%
      • Cash flow breakeven at quarterly revenue of $17 million to $18 million

    About Myomo

    Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

    Forward-Looking Statements

    This press release contains forward-looking statements regarding the Company's future business expectations, including expectations that lead generation had recovered from challenges in the first quarter, that the Company was not reaching a saturation point in its advertising, that the Company was experiencing increasing success in its payer appeals efforts, that contracts had been executed in the process of being executed which cover more than 27 million lives, that it has sufficient manufacturing capacity to produce 250 MyoPros per month, that it could generate 200 basis point of gross margin improvement on a quarterly basis from cost reduction projects by the end of 2026, that the Company's aspiration is to achieve $15 million in annual International revenue by 2028, that the Company's aspiration is to achieve $20 million in O&P channel revenue by 2028, that the Company's aspiration is to achieve $100 million in annual revenue by 2028, with gross margin from 70% to 72%, EBITDA margin from 15% to 20%, and cash flow breakeven revenue of $17 million to $18 million on a quarterly basis, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

    These factors include, among other things:

    • our ability to obtain sufficient reimbursement from third-party payers for our products;
    • our revenue concentration with Medicare and with a particular insurance payer as a result of focusing our efforts on patients with insurers who have previously reimbursed for the MyoPro;
    • our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver and fit our custom-fabricated devices;
    • our marketing and commercialization efforts;
    • our dependence upon external sources for the financing of our operations, to the extent that we do not achieve or maintain cash flow breakeven;
    • our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;
    • our ability to effectively execute our business plan and scale up our operations;
    • our ability to remediate the material weakness in our internal control over financial reporting;
    • our expectations as to our product development programs, including improving our existing products and developing new products;
    • our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;
    • our expectations as to our clinical research program and clinical results;
    • our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;
    • our ability to gain and maintain regulatory approvals;
    • our ability to compete and succeed in a highly competitive and evolving industry; and
    • general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients.

    More information about these and other factors that potentially could affect our financial results is included in Myomo's filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material or adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250618910256/en/

    Myomo

    [email protected]

    Alliance Advisors IR

    Tirth T. Patel

    [email protected]

    212-201-6614

    Get the next $MYO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MYO

    DatePrice TargetRatingAnalyst
    7/31/2024$7.00Buy
    Craig Hallum
    5/20/2024$7.00Buy
    Lake Street
    12/15/2023$6.50Buy
    H.C. Wainwright
    More analyst ratings

    $MYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kirk Thomas F bought $125,993 worth of shares (38,767 units at $3.25), increasing direct ownership by 13% to 344,700 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      5/15/25 4:53:28 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Chief Executive Officer Gudonis Paul R bought $96,612 worth of shares (30,000 units at $3.22), increasing direct ownership by 3% to 1,051,671 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      5/15/25 4:36:08 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Director Kirk Thomas F bought $167,500 worth of shares (50,000 units at $3.35), increasing direct ownership by 20% to 305,933 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      5/14/25 8:27:19 AM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Myomo with a new price target

      Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

      7/31/24 7:20:07 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Lake Street initiated coverage on Myomo with a new price target

      Lake Street initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

      5/20/24 9:00:38 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • H.C. Wainwright initiated coverage on Myomo with a new price target

      H.C. Wainwright initiated coverage of Myomo with a rating of Buy and set a new price target of $6.50

      12/15/23 8:26:14 AM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myomo Provides Highlights of Today's Investor & Analyst Day Event

      Senior executives to provide an in-depth review of the Company's business model and discuss long-range aspirational financial metrics Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, will host an Investor & Analyst Day event today from 10 a.m. to 3 p.m. Eastern time during which management will provide an in-depth review of the Company's business model, provide a tour of its new headquarters and manufacturing facility and discuss long-range aspirational financial metrics. A live and archived webcast of the event is available here. To be held

      6/18/25 8:30:00 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo Reports First Quarter 2025 Financial and Operating Results

      Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was $9.8 million, up 162%; Revenu

      5/7/25 5:11:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Host Investor & Analyst Day Event on June 18, 2025

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the Company will be hosting its first-ever Investor & Analyst Day event on Wednesday, June 18, 2025. The event will take place at Myomo's new corporate headquarters and manufacturing facility in Burlington, Mass., and will offer an in-depth look at the Company's latest innovations, strategic plans and growth initiatives to empower individuals with neuromuscular disorders through cutting-edge wearable medical robotics. Institutional investors, shareholders and analysts are invited to reg

      5/1/25 8:30:00 AM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Kovelman Harry covered exercise/tax liability with 13,054 shares, decreasing direct ownership by 8% to 140,618 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      7/2/25 8:20:13 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Chief Financial Officer Henry David A covered exercise/tax liability with 23,587 shares, decreasing direct ownership by 5% to 427,900 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      7/2/25 8:16:30 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Chief Medical Officer Kovelman Harry was granted 62,938 shares, increasing direct ownership by 69% to 153,672 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      6/13/25 5:14:09 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    SEC Filings

    See more
    • SEC Form 144 filed by Myomo Inc.

      144 - MYOMO, INC. (0001369290) (Subject)

      6/30/25 8:12:58 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MYOMO, INC. (0001369290) (Filer)

      6/18/25 8:40:27 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MYOMO, INC. (0001369290) (Filer)

      6/13/25 4:45:23 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Leadership Updates

    Live Leadership Updates

    See more
    • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

      2/3/25 4:00:00 PM ET
      $INGN
      $MDT
      $MYO
      Industrial Specialties
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Myomo Appoints Heather Getz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

      3/28/24 4:05:00 PM ET
      $BFLY
      $MYO
      Medical Electronics
      Health Care
      Industrial Specialties
    • Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates ("AIGH"), where he has significantly grown AIGH's healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research

      1/30/23 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Financials

    Live finance-specific insights

    See more
    • Myomo Provides Highlights of Today's Investor & Analyst Day Event

      Senior executives to provide an in-depth review of the Company's business model and discuss long-range aspirational financial metrics Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, will host an Investor & Analyst Day event today from 10 a.m. to 3 p.m. Eastern time during which management will provide an in-depth review of the Company's business model, provide a tour of its new headquarters and manufacturing facility and discuss long-range aspirational financial metrics. A live and archived webcast of the event is available here. To be held

      6/18/25 8:30:00 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo Reports First Quarter 2025 Financial and Operating Results

      Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was $9.8 million, up 162%; Revenu

      5/7/25 5:11:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Report First Quarter 2025 Financial Results on May 7

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the cal

      4/30/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      10/18/24 2:21:35 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      7/12/24 10:35:49 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      7/11/24 6:02:07 PM ET
      $MYO
      Industrial Specialties
      Health Care